

**Experiment Number:** 91014-06  
**Test Type:** 26-WEEK  
**Route:** SKIN APPLICATION  
**Species/Strain:** Mouse/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

**Test Compound:** Transgenic LECM (Oleic acid diethanolamine condensate)

**CAS Number:** 93-83-4

**Date Report Requested:** 10/23/2014

**Time Report Requested:** 09:28:39

**First Dose M/F:** NA / NA

**Lab:** ILS

**C Number:** C91014C  
**Lock Date:** 08/21/1997  
**Cage Range:** All  
**Date Range:** All  
**Reasons For Removal:** All  
**Removal Date Range:** All  
**Treatment Groups:** All  
**Study Gender:** Female  
**PWG Approval Date:** NONE

Experiment Number: 91014-06  
 Test Type: 26-WEEK  
 Route: SKIN APPLICATION  
 Species/Strain: Mouse/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
 Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)  
 CAS Number: 93-83-4

Date Report Requested: 10/23/2014  
 Time Report Requested: 09:28:39  
 First Dose M/F: NA / NA  
 Lab: ILS

TG.AC HEMI Mouse FEMALE	0 MG	1.50 UG TPA	0.4 MG	0.8 MG	1.2 MG
<b>Disposition Summary</b>					
Animals Initially In Study	20	10	15	15	19
Early Deaths					
Moribund Sacrifice	2	1			1
Natural Death	1		1	1	2
Survivors					
Terminal Sacrifice	15	7	14	13	13
Other	2	2		1	3
Animals Examined Microscopically	15				13
<b>ALIMENTARY SYSTEM</b>					
Esophagus	(0)	(0)	(0)	(0)	(1)
Liver	(15)	(0)	(0)	(0)	(13)
Hematopoietic Cell Proliferation					1 (8%)
Infiltration Cellular, Mixed Cell	11 (73%)				1 (8%)
Infiltration Cellular, Mononuclear CI	3 (20%)				9 (69%)
Midzonal, Hypertrophy	10 (67%)				10 (77%)
Necrosis	1 (7%)				2 (15%)
Salivary Glands	(15)	(0)	(0)	(0)	(13)
Infiltration Cellular, Lymphocyte	4 (27%)				
Inflammation, Suppurative	1 (7%)				
Stomach, Forestomach	(15)	(0)	(0)	(0)	(13)
Stomach, Glandular	(15)	(0)	(0)	(0)	(13)
Angiectasis					1 (8%)
Cyst					1 (8%)
Tongue	(2)	(0)	(0)	(0)	(3)
Epithelium, Hyperplasia					1 (33%)
Inflammation					2 (67%)
Tooth	(0)	(0)	(0)	(0)	(1)
<b>CARDIOVASCULAR SYSTEM</b>					

a - Number of animals examined microscopically at site and number of animals with lesion

Experiment Number: 91014-06

Test Type: 26-WEEK

Route: SKIN APPLICATION

Species/Strain: Mouse/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**

Test Compound: Transgenic LECM (Oleic acid diethanolamine condensate)

CAS Number: 93-83-4

Date Report Requested: 10/23/2014

Time Report Requested: 09:28:39

First Dose M/F: NA / NA

Lab: ILS

TG.AC HEMI Mouse FEMALE	0 MG	1.50 UG TPA	0.4 MG	0.8 MG	1.2 MG
None					
<b>ENDOCRINE SYSTEM</b>					
Adrenal Cortex	(15)	(0)	(0)	(0)	(13)
Accessory Adrenal Cortical Nodule					1 (8%)
Capsule, Hyperplasia	7 (47%)				9 (69%)
Degeneration, Fatty	14 (93%)				13 (100%)
Mineralization	2 (13%)				5 (38%)
Vacuolization Cytoplasmic	7 (47%)				11 (85%)
Adrenal Medulla	(15)	(0)	(0)	(0)	(13)
Pituitary Gland	(14)	(0)	(0)	(0)	(12)
Thyroid Gland	(15)	(0)	(0)	(0)	(12)
<b>GENERAL BODY SYSTEM</b>					
None					
<b>GENITAL SYSTEM</b>					
Uterus	(1)	(0)	(0)	(0)	(0)
Angiectasis	1 (100%)				
<b>HEMATOPOIETIC SYSTEM</b>					
Lymph Node, Mandibular	(15)	(0)	(0)	(0)	(12)
Infiltration Cellular, Polymorphnuclr					1 (8%)
Spleen	(15)	(0)	(0)	(0)	(13)
Hematopoietic Cell Proliferation	10 (67%)				9 (69%)
Pigmentation, Hemosiderin	7 (47%)				4 (31%)
Thymus	(15)	(0)	(0)	(0)	(12)
Cyst	2 (13%)				3 (25%)
<b>INTEGUMENTARY SYSTEM</b>					
Mammary Gland	(15)	(0)	(0)	(0)	(12)
Skin	(15)	(0)	(0)	(0)	(13)
Dermis, SOA, Fibrosis					3 (23%)

a - Number of animals examined microscopically at site and number of animals with lesion

**Experiment Number:** 91014-06  
**Test Type:** 26-WEEK  
**Route:** SKIN APPLICATION  
**Species/Strain:** Mouse/TG.AC HEMI

**P03: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a)**  
**Test Compound:** Transgenic LECM (Oleic acid diethanolamine condensate)  
**CAS Number:** 93-83-4

**Date Report Requested:** 10/23/2014  
**Time Report Requested:** 09:28:39  
**First Dose M/F:** NA / NA  
**Lab:** ILS

TG.AC HEMI Mouse FEMALE	0 MG	1.50 UG TPA	0.4 MG	0.8 MG	1.2 MG
Dermis, SOA, Inflammation					2 (15%)
Hyperplasia, Squamous					1 (8%)
SOA, Hyperplasia, Squamous	1 (7%)				4 (31%)
SOA, Hyperplasia, Squamous, Focal					2 (15%)
SOA, Ulcer	1 (7%)				2 (15%)
<b>MUSCULOSKELETAL SYSTEM</b>					
None					
<b>NERVOUS SYSTEM</b>					
None					
<b>RESPIRATORY SYSTEM</b>					
Lung	(15)	(0)	(0)	(0)	(13)
Infiltration Cellular, Lymphocyte	5 (33%)				1 (8%)
Infiltration Cellular, Mononuclear Cl					1 (8%)
<b>SPECIAL SENSES SYSTEM</b>					
None					
<b>URINARY SYSTEM</b>					
Kidney	(15)	(0)	(0)	(0)	(13)
Casts Protein	2 (13%)				
Nephropathy	1 (7%)				2 (15%)

**\*\* END OF REPORT \*\***